CLINICAL TRIALS
- ROSS EYE INSTITUTE -
Dr. Andrew Reynolds - Pediatrics
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract.
Enrolling children from birth through age 3 with non-acquired/congenital cataracts.
Learn More: https://clinicaltrials.gov/ct2/show/NCT05191706
Dr. Weiner
Baerveldt 350mm vs. Clear Path 250 mm: recruiting for this study comparing two glaucoma drainage devices.
DECLARE- Glaucoma Drainage Device and Endothelial Cell Loss Compare Trial (DECLARE), seeking enrollment of 25 patients.
Learn More: https://clinicaltrials.gov/ct2/show/NCT04542616
Dr. Sieminiski
A prospective, randomized, multi-center evaluation of the Safety and Effectiveness of the STREAMLINE®SURGICAL SYSTEM compared to iStent Inject W® in Patients with Open-Angle Glaucoma: seeking enrollment of patients with mild-moderate glaucoma undergoing cataract surgery.
Learn More: https://clinicaltrials.gov/ct2/show/NCT05280366
Contact Us
© 2024. Ross Eye Institute.
The Ross Eye Institute website makes every attempt to comply with The Americans with Disabilities Act (ADA) of 1990. If you are using a screen reader and are having problems using this website, please call for assistance.